Related Experiment Video

Updated: May 1, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

8.4K

Polymorphisms of the heart-type fatty acid-binding protein as a prognostic factor in patients with atherosclerosis

Yeongsic Kim1, Soo-Young Kim, Yonggoo Kim

  • 1Departments of Laboratory Medicine, The Catholic University of Korea, Uijeongbu St. Mary's Hospital, 271, Cheon bo-Ro, Uijeong bu, Korea, 480-717; phone: 82 31 820 3159; fax: 82 31 847 6266;

Annals of Clinical and Laboratory Science
|April 4, 2014
PubMed

Insights

Specific FABP3 gene variations may predict outcomes in coronary atherosclerosis patients. A C/G-G/G haplotype in FABP3 SNPs RS2271072 and RS10914367 is linked to a higher risk of myocardial infarction.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetic Epidemiology

Background:

  • Heart-type fatty acid-binding protein (FABP3) levels in cardiomyocytes are implicated in coronary atherosclerosis prognosis.
  • Genetic variations within the FABP3 gene warrant investigation as potential prognostic markers.

Purpose of the Study:

  • To investigate whether single nucleotide polymorphisms (SNPs) in the FABP3 gene serve as prognostic factors in patients with coronary atherosclerosis.
  • To assess the association between specific FABP3 gene SNPs and myocardial infarction (MI) risk.

Main Methods:

  • Genotyping of four FABP3 gene SNPs (RS2271072, RS16834408, RS2279885, and RS10914367) was performed.
  • A cohort of 100 MI patients with coronary atherosclerosis and 100 healthy controls was analyzed.
  • Haplotype analysis was conducted for SNPs RS2271072 and RS10914367.

Main Results:

  • The C/G-G/G haplotype of FABP3 SNPs RS2271072 and RS10914367 was found at a higher frequency (16%) in MI patients compared to healthy individuals (7%).
  • Individuals with the C/G-G/G haplotype exhibited an increased risk of MI (odds ratio: 2.83; 95% CI: 1.01-7.96) compared to those with the G/G-A/A haplotype.

Conclusions:

  • The C/G-G/G haplotype at FABP3 SNPs RS2271072 and RS10914367 may function as a prognostic factor for coronary atherosclerosis.
  • FABP3 gene polymorphisms could contribute to the risk stratification of patients with coronary atherosclerosis and MI.

Keywords:
heart-type fatty acid-binding proteinmyocardial infarctionpolymorphism

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K
Ultrasonic Assessment of Myocardial Microstructure10:53

Ultrasonic Assessment of Myocardial Microstructure

Published on: January 14, 2014

5.1K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K